<DOC>
	<DOCNO>NCT02456207</DOCNO>
	<brief_summary>The primary objective study assess pharmacokinetic ( PK ) similarity SCT400 versus rituximab ( MabThera® ) patient CD20+ B-cell Non-Hodgkin 's Lymphoma . The secondary objective study evaluate pharmacodynamics ( PD ) safety SCT400 versus rituximab ( MabThera® ) , well presence human anti-chimeric antibody ( HACA ) .</brief_summary>
	<brief_title>A Pharmacokinetic Study Comparing SCT400 And Rituximab Patients With B-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1. age 18 75 year ; 2. histologically confirm NHL express CD20 antigen ; 3. obtain CR ( complete remission ) CRu ( uncertain complete remisson ) prior therapy ; 4 . ECOG performance status 0 1 5. expect survival least ≥ 3 month ; 6. sign inform consent form approve institutional review board respective medical center . 1. receive rituximab antiCD20 ( + ) monoclonal antibody treatment within 1 year enrollment ; 2. least 4 week beyond prior anticancer therapy include corticosteroid , recover significant toxicity prior therapy ; 3. participate clinical trial within 30 day enrolment ; 4. serious hematologic dysfunction ( white blood cell count &lt; 3.0×103/uL ; absolute neutrophil count &lt; 1.5×103/ uL ; platelet count &lt; 75×103/uL ; hemoglobin level &lt; 8.0 g/dL ) ; hepatic dysfunction ( total bilirubin level &gt; 1.5×ULN ; aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) level &gt; 2.5 × ULN ; renal dysfunction ( serum creatinine level &gt; 1.5×ULN ) ; International normalize ratio ( INR ) partial thromboplastin time activate partial thromboplastin time ( aPTT ) &gt; 1.5 × ULN ( unless therapeutic coagulation ) ; 5. receive live vaccine within 4 week prior study entry ; 6. malignancy ; central nervous system ( CNS ) lymphoma , AIDSrelated lymphoma ; active opportunistic infection , serious nonmalignant disease ; 7. seropositive HCV antibody , HIV antibody , hepatitis B virus surface antigen ( HBsAg ) . HBc antibody seropositive , HBV DNA HBsAg negative patient may participle follow consultation hepatitis expert regard monitoring use HBV antiviral therapy , provide agree receive treatment indicate , 8. recent major surgery ( within 28 day prior study entry ) ; 9. history allergic reaction protein product allergy include murine protein ; 10. pregnant lactating accept birth control method include male patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>